Fundraising Fox
/Companies
Sign in

Immix Biopharma

Los Angeles, US · Delaware corporation · 1 known investors

Find your way into Immix Biopharma

Sign up to find every way you can get introduced to Immix Biopharma

  • Your email: who you already know at Immix Biopharma, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Immix Biopharma team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Immix Biopharma is a clinical-stage biopharmaceutical company developing NXC-201, a BCMA-targeted CAR-T cell therapy for relapsed/refractory AL amyloidosis and other plasma cell-driven immune diseases. Its lead candidate is being evaluated in the U.S. NEXICART-2 trial and the ex-U.S. NEXICART-1 study, with applications intended for hematology, neurology, rheumatology, and vascular indications.

BiotechHealthtech

Founders & leadership

GM
Gabriel MorrisChief Financial Officer
IRIlya Rachman
Ilya RachmanFounder & Chief Executive Officer
DM
David MarksChief Medical Officer

Board

CN
Carey NgBoard director
MM
Magda MarquetBoard director
JB
Jane BuchanBoard director
HC
Helen C. AdamsBoard director
JH
Jason HsuBoard director
YC
Yekaterina ChudnovskyBoard director

Investors · 1

Reported raises · per SEC filings

Form D private placements
▶Undisclosed amountofferedMay 2024 · 14 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Carey NgDirector
  • Magda MarquetDirector
  • Jane BuchanDirector
  • Helen C. AdamsDirector
  • Gabriel MorrisExecutive Officer, Director
  • Ilya RachmanExecutive Officer, Director
  • Jason HsuDirector
  • Yekaterina ChudnovskyDirector
First sale
May 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Immix Biopharma do?
Immix Biopharma is a clinical-stage biopharmaceutical company developing NXC-201, a BCMA-targeted CAR-T cell therapy for relapsed/refractory AL amyloidosis and other plasma cell-driven immune diseases. Its lead candidate is being evaluated in the U.S. NEXICART-2 trial and the ex-U.S. NEXICART-1 study, with applications intended for hematology, neurology, rheumatology, and vascular indications.
Who founded Immix Biopharma?
Immix Biopharma was founded by Gabriel Morris, Ilya Rachman.
Who are Immix Biopharma's investors?
Immix Biopharma's investors include MESA VERDE VENTURE PARTNERS.
Where is Immix Biopharma headquartered?
Immix Biopharma is headquartered in Los Angeles, US.